I don't think there is anything is the US listing rules that...

I don't think there is anything is the US listing rules that prevents a company putting out a trading update.

The debt in this business means that anyone interested in the tech is going to sit back and buy it off the administrators. Unless sales have gone up massively in the last couple of months then I can't see any way of this death spiral. No instos are going to put in the sort of capital required to get AXP to a sustained sales level without strong growth - a 10% or 20% lift in quarter is not going to do the trick. If there was massive growth there is no way this wouldn't have been announced by the company by now.

There are a lot of lesson in AXP, not least that a good product and FDA approval doesn't equal commercial success and that surgeons are not a good customers. They are far too conservative and don't really care about their patients - this is why a lot of them went into surgery in the first place so they don't want to deal with patients. Doc Martin might be a TV character stereotype, but there is a reason why the writers made him a surgeon.